vTv Therapeutics (VTVT) Competitors

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

$24.74

+0.59 (+2.44%)

(As of 04/18/2024 ET)

VTVT vs. BYSI, ASMB, ACRS, AVRO, BLRX, SABS, BCLI, LIAN, ACST, and LPCN

Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include BeyondSpring (BYSI), Assembly Biosciences (ASMB), Aclaris Therapeutics (ACRS), AVROBIO (AVRO), BioLineRx (BLRX), SAB Biotherapeutics (SABS), Brainstorm Cell Therapeutics (BCLI), LianBio (LIAN), Acasti Pharma (ACST), and Lipocine (LPCN). These companies are all part of the "medical" sector.

vTv Therapeutics vs.

vTv Therapeutics (NASDAQ:VTVT) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.

: vTv Therapeutics received 166 more outperform votes than BeyondSpring when rated by MarketBeat users. However, 66.79% of users gave BeyondSpring an outperform vote while only 57.83% of users gave vTv Therapeutics an outperform vote.
Company Underperform Outperform
vTv Therapeutics Outperform Votes
351
57.83%
Underperform Votes
256
42.17%
BeyondSpring Outperform Votes
185
66.79%
Underperform Votes
92
33.21%
: BeyondSpring has a consensus target price of $1.25, indicating a potential downside of 30.56%. Given BeyondSpring's higher probable upside, analysts plainly believe BeyondSpring is more favorable than vTv Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
BeyondSpring
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Company Net Margins Return on Equity Return on Assets
vTv Therapeutics N/A N/A -104.93%
BeyondSpring N/A N/A N/A
: 17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 1.7% of vTv Therapeutics shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: In the previous week, vTv Therapeutics' average media sentiment score of 1.92 beat BeyondSpring's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
vTv Therapeutics Very Positive
BeyondSpring Neutral
: vTv Therapeutics has higher revenue and earnings than BeyondSpring.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
vTv Therapeutics $2.02M 36.87 -$20.25M -$10.07 -2.46
BeyondSpring $1.35M 51.89 -$33.28M N/A N/A
: vTv Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Company	Underperform	Outperform
vTv Therapeutics	Outperform Votes 351 57.83%	Underperform Votes 256 42.17%
BeyondSpring	Outperform Votes 185 66.79%	Underperform Votes 92 33.21%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
BeyondSpring	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	N/A	-104.93%
BeyondSpring	N/A	N/A	N/A

Company	Overall Sentiment
vTv Therapeutics	Very Positive
BeyondSpring	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$2.02M	36.87	-$20.25M	-$10.07	-2.46
BeyondSpring	$1.35M	51.89	-$33.28M	N/A	N/A

Summary

BeyondSpring beats vTv Therapeutics on 6 of the 11 factors compared between the two stocks.

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Get vTv Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTVT vs. The Competition

Export to Excel

Metric	vTv Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$74.47M	$6.45B	$4.77B	$7.44B
Dividend Yield	N/A	2.97%	3.00%	4.00%
P/E Ratio	-2.46	17.71	254.51	19.15
Price / Sales	36.87	330.89	2,420.87	85.86
Price / Cash	N/A	20.94	47.48	35.12
Price / Book	-2.67	5.48	4.59	4.19
Net Income	-$20.25M	$147.46M	$104.46M	$214.15M
7 Day Performance	0.77%	-7.89%	-5.35%	-4.91%
1 Month Performance	18.37%	-7.77%	-4.82%	-3.49%
1 Year Performance	-18.62%	-3.66%	8.55%	3.83%

vTv Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.0033 of 5 stars	$1.80 +2.3%	$1.25 -30.6%	+32.4%	$70.06M	$1.35M	0.00	73	Positive News
ASMB Assembly Biosciences	1.0591 of 5 stars	$14.72 -1.4%	N/A	+1.9%	$80.67M	$7.16M	-0.86	65
ACRS Aclaris Therapeutics	1.3795 of 5 stars	$1.22 +0.8%	$22.25 +1,723.8%	-86.7%	$86.54M	$31.25M	-0.96	86
AVRO AVROBIO	1.8288 of 5 stars	$1.26 flat	$2.00 +58.7%	+37.2%	$56.52M	N/A	-12.60	13	News Coverage
BLRX BioLineRx	1.6371 of 5 stars	$0.64 flat	$21.00 +3,181.3%	-40.2%	$51.16M	$4.80M	-0.71	79	Analyst Report Gap Up
SABS SAB Biotherapeutics	1.4172 of 5 stars	$4.72 +2.4%	$15.50 +228.4%	+304.6%	$43.57M	$2.24M	0.00	57	Analyst Report Gap Up
BCLI Brainstorm Cell Therapeutics	1.234 of 5 stars	$0.53 -3.7%	N/A	-80.7%	$36.02M	N/A	-1.29	29	Gap Down
LIAN LianBio	0.6482 of 5 stars	$0.30 +3.4%	$5.33 +1,676.6%	-85.9%	$32.44M	N/A	-0.37	163	Gap Up
ACST Acasti Pharma	3.051 of 5 stars	$3.37 +0.3%	$6.00 +78.0%	+6.5%	$31.68M	N/A	-0.66	32	News Coverage
LPCN Lipocine	0 of 5 stars	$4.76 -11.2%	N/A	+5.2%	$25.32M	$500,000.00	-1.56	17	Gap Up

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

vTv Therapeutics (VTVT) Competitors

VTVT vs. BYSI, ASMB, ACRS, AVRO, BLRX, SABS, BCLI, LIAN, ACST, and LPCN

vTv Therapeutics vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info